Roivant Sciences Ltd. vs Abbvie Inc.
ROIV vs ABBV — side-by-side comparison from reported financials. ROIV leads 4, ABBV leads 6 of 10 comparable metrics.
Roivant Sciences Ltd.
ROIV · Healthcare
$35.44+3.60%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | ROIV | ABBV |
|---|---|---|
| Price | $35.44 | $276.43 |
| Market cap | $25.6B | $488B |
| Revenue (TTM) | $16.9M | $64.4B |
| Revenue growth | -48.7% | +1.8% |
| Net margin | -7594.2% | 9.8% |
| Free cash flow | -$1.89B | $18.2B |
| Net cash (debt) | $3.73B | ($56.2B) |
| 1-year price return | +119.9% | +19.8% |
| P/E | — | 77.4 |
| P/E vs own history (cheap-side %) | 73% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -6% | 96% |
| Altman Z-score | 40.50 | 2.33 |
| CV checks passed | 5 of 9 | 9 of 9 |
| Employees | 721 | 57,000 |
Full résumé-style profiles: ROIV CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.